Actively Recruiting
Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.
Led by Yongquan Shi · Updated on 2026-03-27
150
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.
CONDITIONS
Official Title
Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years old, any gender
- Patients with chronic radiation intestinal injury causing bleeding symptoms confirmed by clinical, endoscopic, imaging, and histopathological findings
- Exposure to radioactive sources with exclusion of tumor activity or recurrence
- At least 20% of bowel movements in the week before treatment involve bleeding
- ECOG performance score of 0 to 2
You will not qualify if you...
- Hemodynamic instability
- Significant liver or kidney damage (bilirubin or liver enzymes over twice the normal limit; eGFR below 60 ml/min or on dialysis)
- Allergy to thalidomide or glutamine
- Primary gastrointestinal cancer
- Serious or uncontrolled diseases of blood, digestive tract, metabolism, endocrine, lung, heart, nervous or mental systems
- Pregnancy or breastfeeding, including reproductive needs
- HIV infection
- Inability to comply with regular follow-up and lab tests
- Any other condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Ch
Xi'an, Shaanxi, China, 710005
Actively Recruiting
Research Team
Y
Yongquan Shi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here